Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04102761 · ClinicalTrials.gov registry record · NA

The Use of PRP and BMC in Patients With Internal Disc Disruption Multicenter Prospective Randomized Controlled Trial in Patients With Internal Disc Disruption

A NA study of Internal Disc Disruption, sponsored by Annu Navani.

Completed
Registry status
NA
Development phase
45
Enrollment target
4
Study locations

NCT04102761 is a NA study of Internal Disc Disruption that has completed, run by Annu Navani. The registered enrollment target is 45 participants. The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04102761, a NA study of Internal Disc Disruption, has completed, sponsored by Annu Navani.

COMPLETED
Registry status
NA
Development phase
45 participants
Enrollment target
4
Study locations

Study Summary

The condition being studied is chronic low back or leg pain in patients with internal disc disruption (IDD). The intervention to be studied is the intradiscal delivery of autologous Platelet Rich Plasma (PRP) or bone marrow concentrate (BMC) into the nucleus pulposus of the disrupted disc(s).

Conditions Studied

Interventions

  • PROCEDURE Intradiscal PRP & BMC Injections

Study Locations (4)

California

  • Alex Hames - Campbell
  • The Orthohealing Center - Los Angeles

Texas

  • Texas Spine and Joint Hospital - Tyler

Utah

  • Nexus Pain Care - Provo

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2018-03-27
Est. Completion 2020-12-31
Phase NA

Sponsor

Annu Navani

1 total trials

What the Registry Record Tells You About NCT04102761

The ClinicalTrials.gov registry entry for NCT04102761 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Annu Navani, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Internal Disc Disruption appearing as the primary indexed condition, and to 1 intervention - of which Intradiscal PRP & BMC Injections is the first listed.

NCT04102761 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Texas, Utah.

Frequently Asked Questions

What is clinical trial NCT04102761 about?

NCT04102761 is a clinical study titled "The Use of PRP and BMC in Patients With Internal Disc Disruption Multicenter Prospective Randomized Controlled Trial in Patients With Internal Disc Disruption". The condition being studied is chronic low back or leg pain in patients with internal disc disruption (IDD). The intervention to be studied is the intradiscal delivery of autologous Platelet Rich Plasma (PRP) or bone marrow concentrate (BMC) into the nucleus pulposus of the disrupted disc(s).

What is the current status of trial NCT04102761?

This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2018-03-27. Estimated completion is 2020-12-31.

What conditions does trial NCT04102761 study?

This clinical trial studies the following conditions: Internal Disc Disruption.

What interventions are being tested in trial NCT04102761?

The interventions under investigation include: Intradiscal PRP & BMC Injections (PROCEDURE).

Who is sponsoring clinical trial NCT04102761?

This trial is sponsored by Annu Navani, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04102761 being conducted?

This trial has 4 study locations across California, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.